午夜久久精品国产亚洲av,欧美日韩一区二区三区免费,国产视频一区二区三区久久亚洲

規(guī)格	庫(kù)存	目錄價(jià)	會(huì)員專(zhuān)享價(jià)	數(shù)量
暫無(wú)牌價(jià)信息，您可以發(fā)送詢(xún)價(jià)，我們會(huì)盡快給你回復(fù)。

規(guī)格

庫(kù)存

目錄價(jià)

會(huì)員專(zhuān)享價(jià)

數(shù)量

暫無(wú)牌價(jià)信息，您可以發(fā)送詢(xún)價(jià)，我們會(huì)盡快給你回復(fù)。

基本信息

英文名稱(chēng)	Anti-Human PD-1xCTLA-4 Bispecific Antibody(Cadonilimab)
中文名稱(chēng)	卡度尼利單抗
CAS號(hào)	2394841-59-7
儲(chǔ)存條件	-80°C for one-year storage. Avoid repeated freeze-thaw.

安全信息

產(chǎn)品詳情

Cadonilimab is a pioneering bispecific antibody targeting PD-1 and CTLA-4,it blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC).

相關(guān)文獻(xiàn)

Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice.

PMID: 38677243 DOI: 10.1016/j.biopha.2024.116669

PMID: 37600791 PMCID: PMC10435079 DOI: 10.3389/fimmu.2023.1188523

Antibodies to watch in 2022.

PMID: 35030985 PMCID: PMC8765076 DOI: 10.1080/19420862.2021.2014296

PMID: 34577584 PMCID: PMC8468026 DOI: 10.3390/ph14090884

相關(guān)產(chǎn)品

抱歉，暫時(shí)沒(méi)有相關(guān)產(chǎn)品

瀏覽記錄